Morgan Stanley Aveo Pharmaceuticals, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$8.48 - $14.97 $3.47 Million - $6.13 Million	409,624 Added 388.36%	515,099 $7.7 Million
Q3 2022 Nov 14, 2022	BUY	$6.61 - $8.72 $392,845 - $518,247	59,432 Added 129.08%	105,475 $869,000
Q2 2022 Oct 27, 2022	BUY	$3.51 - $6.67 $6,679 - $12,693	1,903 Added 4.31%	46,043 $302,000
Q2 2022 Aug 15, 2022	BUY	$3.51 - $6.67 $6,679 - $12,693	1,903 Added 4.31%	46,043 $302,000
Q1 2022 Oct 27, 2022	SELL	$3.15 - $6.01 $5,994 - $11,437	-1,903 Reduced 4.13%	44,140 $246,000
Q1 2022 May 13, 2022	BUY	$3.15 - $6.01 $37,963 - $72,432	12,052 Added 37.56%	44,140 $246,000
Q4 2021 Feb 14, 2022	SELL	$4.69 - $7.4 $186,793 - $294,727	-39,828 Reduced 55.38%	32,088 $151,000
Q3 2021 Nov 15, 2021	BUY	$5.12 - $6.89 $368,209 - $495,501	71,916 New	71,916 $445,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.